Clinical trial
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
NCT00309907 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
- Lead sponsor
- Children's Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- September 30, 2011
- Enrollment
- 39 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood chronic myelogenous leukemia, childhood myelodysplastic syndromes, chronic phase chronic myelogenous leukemia, de novo myelodysplastic syndromes, disseminated neuroblastoma, juvenile myelomonocytic leukemia, previously treated childhood rhabdomyosarcoma, previously treated myelodysplastic syndromes, pulmonary complications, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood rhabdomyosarcoma, recurrent childhood small noncleaved cell lymphoma, recurrent neuroblastoma, recurrent wilms tumor and other childhood kidney tumors, recurrent/refractory childhood hodgkin lymphoma, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, secondary myelodysplastic syndromes